Janus Henderson Group PLC Raises Holdings in Catalyst Pharmaceuticals, Inc. $CPRX

Janus Henderson Group PLC increased its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 16.2% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,998,875 shares of the biopharmaceutical company’s stock after buying an additional 279,108 shares during the period. Janus Henderson Group PLC owned about 1.63% of Catalyst Pharmaceuticals worth $49,520,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of CPRX. Parkside Financial Bank & Trust increased its holdings in shares of Catalyst Pharmaceuticals by 17.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 469 shares during the period. Oregon Public Employees Retirement Fund increased its position in Catalyst Pharmaceuticals by 1.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 26,428 shares of the biopharmaceutical company’s stock valued at $617,000 after buying an additional 472 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Catalyst Pharmaceuticals by 4.7% during the first quarter. PNC Financial Services Group Inc. now owns 10,554 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 474 shares in the last quarter. Lifestyle Asset Management Inc. increased its stake in Catalyst Pharmaceuticals by 3.4% during the 4th quarter. Lifestyle Asset Management Inc. now owns 16,835 shares of the biopharmaceutical company’s stock valued at $393,000 after purchasing an additional 553 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its position in shares of Catalyst Pharmaceuticals by 55.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 630 shares during the period. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ:CPRX opened at $31.49 on Friday. The business has a 50-day moving average price of $31.41 and a 200 day moving average price of $27.60. The company has a market capitalization of $3.86 billion, a price-to-earnings ratio of 18.10, a PEG ratio of 0.96 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a 12-month low of $19.05 and a 12-month high of $32.56.

Wall Street Analyst Weigh In

CPRX has been the topic of several research reports. Stephens set a $32.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, May 7th. Zacks Research lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Robert W. Baird lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Oppenheimer cut Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Finally, HC Wainwright cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the company from $35.00 to $31.50 in a research report on Thursday, May 28th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Catalyst Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $32.00.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).